Two cotadutide suppliers may advertise identical purity percentages while providing very different analytical evidence.
When comparing cotadutide research peptide suppliers, UK laboratories should examine what each certificate of analysis (COA) actually demonstrates, which batch was tested and whether the methods support the reported findings.
A COA is useful only when its information can be connected to the material offered.
What Should a Cotadutide COA Contain?
Cotadutide, also known as MEDI0382, is a peptide studied for activity at GLP-1 and glucagon receptors.
A supplier COA should provide enough information to evaluate the specified material.
Key elements include:
- Compound name and relevant molecular specifications.
- Unique batch or lot identifier.
- Analytical methods and reported results.
- Identity evidence, potentially including mass spectrometry.
- Chromatographic purity information.
- Testing date and identifiable issuing laboratory.
Additional testing may be required depending on the research protocol.
Comparing Three Hypothetical Supplier COAs
The examples below are illustrative, not assessments of actual businesses.
| Evidence | Supplier A | Supplier B | Supplier C |
|---|---|---|---|
| Batch number | Provided | Missing | Provided |
| Identity evidence | MS report | Not supplied | MS report |
| HPLC method | Described | Purity figure only | Described |
| Chromatogram | Available | Missing | Available |
| Matches offered batch | Yes | Unclear | No |
Supplier A: Provides the most complete documentation in this example.
Supplier B: Requires clarification because its reported purity cannot be properly assessed.
Supplier C: Provides analytical records, but they relate to a different batch. Replacement documentation is necessary.
How to Interpret Purity Results
An HPLC area percentage indicates the proportion of detected chromatographic signal assigned to a component under specified analytical conditions.
It does not automatically establish peptide content by mass, complete molecular identity, sterility or endotoxin status.
A supplier reporting 99% HPLC area purity should not automatically outrank one reporting 98.5% using a different method.
Laboratories should review method suitability, impurity information and their own acceptance criteria.
A Practical Documentation Decision
| Decision | Evidence status |
|---|---|
| Accept for procurement review | Required records are complete and correspond to the offered batch |
| Request clarification | Information is missing or methods are insufficiently described |
| Withhold approval | Critical identity or batch discrepancies remain unresolved |
For broader product checks, read our cotadutide laboratory ordering guide.
Frequently Asked Questions
1. Does every COA confirm peptide identity?
No. The analytical methods and evidence determine what it supports.
2. Is 99% HPLC purity sufficient?
Not alone. Identity and other relevant specifications require assessment.
3. Should a COA identify the tested batch?
Yes. Batch identification supports traceability.
4. Can different HPLC results be compared directly?
Only when the methods and reporting approaches are sufficiently comparable.
5. What if a COA belongs to another batch?
Request documentation corresponding to the offered material.
6. Does a COA establish receptor activity?
Not unless suitable functional testing is included.
Conclusion
Comparing cotadutide research peptide suppliers requires more than ranking purity percentages. Prioritise batch correspondence, transparent analytical methods and evidence that supports the stated product identity.
For laboratory research only. Not intended for human administration or clinical use.
Scientific and Technical References
- ICH Q2(R2) — Validation of Analytical Procedures: https://www.ich.org/page/quality-guidelines
- ICH Q6B — Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products: https://www.ich.org/page/quality-guidelines
- ClinicalTrials.gov — Cotadutide research records: https://clinicaltrials.gov/search?term=cotadutide
These references provide general analytical and scientific context, not verification of any individual supplier’s COA.
One thought on “Cotadutide Research Peptide Suppliers: How to Compare COA Documentation”